Forecast

The analysts' average price target is +53,89€ (+19,60%). The median is +55,78€ (+23,79%).

Buy	5
Hold	0
Sell	0

News Go to news feed

Rapport Therapeutics reaches record high at $44.38

Rapport Therapeutics shares rose to a new all-time high of $44.38 and are up about 190% year to date; the six-month performance is 57%. With a market capitalization of roughly $2.03 billion, an InvestingPro analysis classifies the stock as overvalued, and analysts do not expect profitability this year. Several firms initiated or confirmed positive ratings and price targets (including William Blair $79.03, Leerink $52.00, Citizens $80.00, Truist $56.00, Stifel $56.00); phase-2 results for RAP-219 in bipolar mania are expected in Q4 2026. » More on de.investing.com
Rapport Therapeutics reaches all-time high at $44.28

Shares of Rapport Therapeutics rose to a record high of $44.28, giving a gain of about 177.11% over the past year. Market capitalization is roughly $2 billion, while earnings per share for the last twelve months are -$2.56. Analyst ratings vary: William Blair (outperform, fair value $79.03), Leerink (outperform, $52), Truist (buy, target $56), Stifel (buy, $56) and Citizens (market outperform, $80). InvestingPro classifies the stock as overvalued; quarterly results are expected in nine days. » More on de.investing.com
Rapport Therapeutics hits record high at $42.36

Shares of Rapport Therapeutics climbed to a record high of $42.36, reflecting a 266.84% increase over the past year and a market capitalization of about $1.93 billion. InvestingPro currently rates the stock as overvalued and does not expect profitability this year. The company moved forward the expected release of Phase‑2 results for RAP‑219 in bipolar mania to Q4 2026, raised recruitment targets and adjusted the statistical analysis plan. Several analysts reaffirmed or raised their ratings (including Stifel, Truist, Raymond James, Leerink, Citizens) and set price targets between $44 and $80. » More on de.investing.com

Financials

In the last quarter, Rapport Therapeutics had revenue of 0.00€ and net profit of −49.61m€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	0.00	-
Net profit	−49.61m	118,72%
EBITDA	−49.22m	98,39%

Fundamentals

Metric	Value
Market capitalization	+2.10b€
Number of shares	47.83m
52-week high/low	+44,09€ - +12,11€
Dividends	No
Beta	0,97
P/E ratio	−16,83
PEG ratio	+0,78
P/B ratio	+5,74
P/S ratio	+122,37

Company profile

Rapport Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entdeckung und Entwicklung von bahnbrechenden niedermolekularen Medikamenten für Patienten mit Erkrankungen des zentralen Nervensystems (ZNS) konzentriert. Sein führender Produktkandidat ist das rezeptorassoziierte Protein (RAP)-219, ein kleines Molekül, das TARPy8-haltige AMPARs mit picomolarer Affinität hemmen soll, um fokale Epilepsie und andere ZNS-Erkrankungen zu behandeln, darunter periphere neuropathische Schmerzen und bipolare Störungen. Das Unternehmen entwickelt außerdem RAP-199, ein zielgerichtetes TARPy8-Molekül mit differenzierten chemischen und pharmakokinetischen Eigenschaften, sowie Programme für nikotinische Acetylcholinrezeptoren (nAChR), wie a6 nAChR zur Behandlung chronischer Schmerzen und a9a10 nAChR zur Behandlung von Hörstörungen. Das Unternehmen war früher als Precision Neuroscience NewCo, Inc. bekannt und änderte im Oktober 2022 seinen Namen in Rapport Therapeutics, Inc. Rapport Therapeutics, Inc. wurde im Jahr 2022 gegründet und hat seinen Sitz in Boston, Massachusetts.